Patents for A61P 35 - Antineoplastic agents (221,099) |
---|
10/28/2014 | US8871708 Compositions and methods for treating AIDS or cancer by inhibiting the secretion of microparticles |
10/28/2014 | US8871436 Immunostimulatory oligonucleotides and uses thereof |
10/28/2014 | US8871253 Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
10/28/2014 | US8871193 Viral vectors and their use in therapeutic methods |
10/23/2014 | US20140315978 Compositions and Methods for Treatment of Prostate and Other Cancers |
10/23/2014 | US20140314714 Immunopotentiative composition |
10/21/2014 | US8865726 Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
10/21/2014 | US8865720 Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
10/21/2014 | US8865709 Aminooxazole inhibitors of cyclin dependent kinases |
10/21/2014 | US8865690 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
10/21/2014 | US8865686 Tetracycline compounds as tyrosyl-DNA phosphodiesterase I inhibitors |
10/21/2014 | US8865663 Method for the administration of anti-cancer drugs |
10/21/2014 | US8865656 Beta-hairpin peptidomimetics having CXCR4 antagonizing activity |
10/21/2014 | US8865653 Method of treatment for immunogenic treatment resistant cancer |
10/21/2014 | US8865652 Method of treating solid cancers with pegylated IL-10 |
10/21/2014 | US8865643 Recombinant surfactant protein D compositions and methods of use thereof |
10/21/2014 | US8865642 Natural plant products for control of cancer metastasis |
10/16/2014 | US20140309174 Hemiasterlin derivatives and uses thereof in the treatment of cancer |
10/16/2014 | US20140308288 Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
10/14/2014 | US8859855 Chimeric PUFA polyketide synthase systems and uses thereof |
10/14/2014 | US8859747 Promoters exhibiting endothelial cell specificity and methods of using same |
10/14/2014 | US8859745 Promoters exhibiting endothelial cell specificity and methods of using same |
10/14/2014 | US8859729 Growth hormone releasing peptides |
10/14/2014 | US8859723 Peptidomimetic macrocycles |
10/14/2014 | US8859594 Polymorphs of N-(6-(4-chlorophenoxy)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine, and preparation thereof and use thereof |
10/14/2014 | US8859574 Compounds and compositions as kinase inhibitors |
10/14/2014 | US8859546 Picolinamide inhibitors of kinases |
10/14/2014 | US8859488 Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
10/09/2014 | WO2014165786A1 Cabozantinib dosage form and use in the treatment of cancer |
10/09/2014 | WO2014165779A1 Drug combinations to treat cancer |
10/09/2014 | WO2014165736A2 Esters of 2-deoxy-monosaccharides with anti proliferative activity |
10/09/2014 | WO2014165718A1 Combination therapy for the treatment of proliferative diseases |
10/09/2014 | WO2014165714A1 Specific pomegranate juice compoments and inhibition of prostate cancer progression/metastasis |
10/09/2014 | WO2014165581A1 Gpr15-mediated homing and uses thereof |
10/09/2014 | WO2014165482A1 Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
10/09/2014 | WO2014165296A1 Methods and formulations to achieve tumor targeted double stranded rna mediated cell death |
10/09/2014 | WO2014165103A1 Individualized high-purity glioblastoma multiforme stem cells and methods for stimulating immune response |
10/09/2014 | WO2014165101A1 Individualized high purity colon carcinoma stem cells, methods and use of the same |
10/09/2014 | WO2014164988A1 Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications |
10/09/2014 | WO2014164942A1 Dual mek/pi3k inhibitors and therapeutic methods using the same |
10/09/2014 | WO2014164784A1 Hdac inhibitor polymorphic forms and methods of use |
10/09/2014 | WO2014164780A1 Fused tetracyclic bromodomain inhibitors |
10/09/2014 | WO2014164771A1 Bromodomain inhibitors |
10/09/2014 | WO2014164729A1 Substituted tricyclic pyrazolo-pyrimidine compounds |
10/09/2014 | WO2014164596A1 Bet bromodomain inhibitors and therapeutic methods using the same |
10/09/2014 | WO2014164558A1 Pyridinyl and fused pyridinyl triazolone derivatives |
10/09/2014 | WO2014164554A1 Chemotherapy-resistant immune cells |
10/09/2014 | WO2014164464A1 High purity ovarian cancer stem cells for active autologous immune therapy |
10/09/2014 | WO2014164462A1 Method of induction and purification of a cell population responsible for vasculary mimicry and use of the same |
10/09/2014 | WO2014164396A1 Ablative immunotherapy |
10/09/2014 | WO2014164395A1 Combination anti-estrogen receptor cancer therapy using muc1 peptides and chemotherapeutics |
10/09/2014 | WO2014164394A1 Combination anti-her2 cancer therapy using muc1 peptides and chemotherapeutics |
10/09/2014 | WO2014163535A1 Chimeric peptide and pharmaceutical composition for treating oncological diseases |
10/09/2014 | WO2014163513A1 Therapeutic compositions and uses thereof |
10/09/2014 | WO2014163512A1 Therapeutic compositions comprising extracts of propolis and uses thereof |
10/09/2014 | WO2014163278A1 Composition for protecting against radioactivity comprising fisetin compound as active ingredient |
10/09/2014 | WO2014163101A1 Fc region variant |
10/09/2014 | WO2014162962A1 Tumor antigen peptide |
10/09/2014 | WO2014162039A1 Protein kinase inhibitors |
10/09/2014 | WO2014161938A1 Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor |
10/09/2014 | WO2014161845A1 Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
10/09/2014 | WO2014161808A1 Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]jpyridin-5-yl)-4- quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4- quinazolinamine derivatives as perk inhibitors |
10/09/2014 | WO2014161240A1 Preparation method and application of anti-tumor active polypeptide component in scapharca subcrenatae |
10/09/2014 | WO2014161046A1 Methods of treating diseases characterized by excessive wnt signalling |
10/09/2014 | WO2014161037A1 Antibodies against human ryk and uses therefor |
10/09/2014 | WO2014161031A1 Nanoparticles for drug delivery comprising albumin having a polymer chain coupled thereto |
10/09/2014 | US20140303257 Use of EDG Receptor Binding Agents in Cancer |
10/09/2014 | US20140303208 Pharmaceutically active piperidine derivatives |
10/09/2014 | US20140303146 Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias |
10/09/2014 | US20140303077 Albumin fusion proteins |
10/09/2014 | US20140302499 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors |
10/09/2014 | US20140302018 Treatment of diffuse large-cell lymphoma with anti-cd20 antibody |
10/08/2014 | EP2787002A1 Oleanolic acid amidate derivatives, preparation methods and uses thereof |
10/08/2014 | EP2787001A1 (E)-3-Aryl-3-oxoprop-1-enyl-2-phosphonic acid and its derivatives, methods for their preparation and their use |
10/08/2014 | EP2786996A1 Purinone derivative hydrochloride |
10/08/2014 | EP2786990A1 2-aminated methylene or 2-esterified methylene tanshinone derivatives, and preparation method and application thereof |
10/08/2014 | EP2786989A1 2-alkyl-or-aryl-substituted tanshinone derivatives, and preparation method and application thereof |
10/08/2014 | EP2786981A1 Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof |
10/08/2014 | EP2786765A2 Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor |
10/08/2014 | EP2786764A2 Combination therapy using anti-c-met antibody and sorafenib |
10/08/2014 | EP2786757A1 2-substituted oleanolic acid derivative, method preparing for same, and application thereof |
10/08/2014 | EP2786756A2 Combination therapy with an antitumor alkaloid |
10/08/2014 | EP2786755A2 Combination therapy with an antitumor alkaloid |
10/08/2014 | EP2786754A2 Combination therapy with an antitumor alkaloid |
10/08/2014 | EP2786753A2 Combination therapy with an antitumor alkaloid |
10/08/2014 | EP2786750A1 Agent for reducing adverse side effects of kinase inhibitor |
10/08/2014 | EP2785872A2 Materials and methods related to nsaid chemoprevention in colorectal cancer |
10/08/2014 | EP2785871A1 A ctc biomarker assay to combat breast cancer brain metastasis |
10/08/2014 | EP2785842A1 Hpv chimaeric particle |
10/08/2014 | EP2785766A1 Hydroxypolyamine salts |
10/08/2014 | EP2785744A1 Protein inhibitors to complement and vegf pathways and methods of use thereof |
10/08/2014 | EP2785743A1 Anti-ceacam1 recombinant antibodies for cancer therapy |
10/08/2014 | EP2785742A1 Anti-kdr antibodies and methods of use |
10/08/2014 | EP2785741A1 Antibodies against hgf - receptor and uses |
10/08/2014 | EP2785738A1 Anti-npy and pyy antibodies and uses thereof |
10/08/2014 | EP2785720A1 Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
10/08/2014 | EP2785717A1 Pyrazolopyrrolidine compounds |
10/08/2014 | EP2785714A1 Improved modulators of hec1 activity and methods therefor |
10/08/2014 | EP2785712A1 Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof |
10/08/2014 | EP2785701A2 Crystalline forms of carbazitaxel and process for preparation thereof |